Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 08-10, 2025. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex' ...

财务数据和关键指标变化 - 未提及相关内容 各条业务线数据和关键指标变化 - 完成研发阶段，GABAB正变构调节剂项目取得多项候选药物[6] - 合作伙伴Indivior选择一种化合物用于物质使用障碍的开发，并已开始研发支持性研究[6] 各个市场数据和关键指标变化 - 未提及相关内容 公司战略和发展方向和行业竞争 - 未提及相关内容 管理层对经营环境和未来前景的评论 - 未提及相关内容 其他重要信息 - 提醒关注今天早些时候发布的新闻稿和财务报表以及免责声明，会议中会有前瞻性陈述[4] 问答环节所有的提问和回答 问题: 未提及相关内容 - 未提及相关内容

Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corpo ...

Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024. The provisional result for the third quarter of 2024 show a net ...

Investors might want to bet on Addex Therapeutics Ltd. Sponsored ADR (ADXN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is ...

财务数据和关键指标变化 - 公司在Q2 2024实现收入0.1百万瑞士法郎,相比Q2 2023的0.6百万瑞士法郎有所下降 [23] - 持续经营的研发费用在Q2 2024保持稳定,为0.3百万瑞士法郎 [23] - 持续经营的管理费用在Q2 2024也保持稳定,为0.7百万瑞士法郎 [23] - 公司在Q2 2024完成时持有3.8百万瑞士法郎的现金 [24] 各条业务线数据和关键指标变化 - 公司与Indivior合作的GABAB PAM项目取得进展,Indivior已选定一个候选化合物用于药物滥用障碍的开发,预计2025年上半年开始IND使能研究 [7][16] - 公司自主开发的GABAB PAM慢性咳嗽项目也取得进展,临床候选化合物已完成前期研究,计划2025年上半年开始IND使能研究 [15-20] - 公司之前开发的dipraglurant项目已终止帕金森病相关的适应症开发,但公司正在评估将其用于脑损伤恢复的可能性 [10-14] 各个市场数据和关键指标变化 - 未提及具体市场数据和指标变化 公司战略和发展方向及行业竞争 - 公司通过将早期研发项目(M4PAM、mGlu7 NAM和mGlu2 NAM)剥离至子公司Neurosterix的方式,获得了6300万美元的融资,同时保留了20%的股权,为自身的临床阶段资产和合作项目提供了资金支持 [21-22] - 公司认为GABAB PAM在慢性咳嗽治疗中具有优势,可能提供更好的疗效和耐受性,与现有标准治疗如P2X3抑制剂Camlipixant相比有望在更广泛的患者群中获得更好的疗效 [31][33-34] 管理层对经营环境和未来前景的评论 - 管理层认为公司目前处于一个良好的战略位置,通过Neurosterix交易加强了资产负债表,为公司的临床前项目提供了所需的资金支持 [30] - 管理层对公司GABAB PAM慢性咳嗽项目和与Indivior合作的GABAB PAM药物滥用项目的前景表示乐观 [30] - 管理层对公司重新定位dipraglurant用于脑损伤恢复的前景也表示乐观 [30] 其他重要信息 - 由于技术问题,本次会议无法正常播放PPT,与会者需要自行下载PPT文件进行查看 [3-4] 问答环节重要的提问和回答 问题1 **Raghuram Selvaraju 提问** 询问公司慢性咳嗽项目的具体适应症方向 [28] **Tim Dyer 回答** 公司目前正在考虑难治性和原因不明的慢性咳嗽,以及COPD或特发性肺纤维化相关的慢性咳嗽作为潜在的适应症 [29] 问题2 **Raghuram Selvaraju 提问** 询问公司对慢性咳嗽项目的临床对照药物的预期 [31] **Tim Dyer 和 Misha Kalinichev 回答** 公司将以GABAB受体激动剂如baclofen以及其他GABAB PAM化合物作为临床对照,同时也会与最新批准的P2X3抑制剂Camlipixant进行对比 [32-34] 问题3 **Raghuram Selvaraju 提问** 询问Neurosterix子公司未来的上市计划 [41] **Tim Dyer 回答** 对Neurosterix的未来策略,包括是否上市,公司无法在此次会议上进行评论 [41]

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sà ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Addex Therapeutics Ltd. Sponsored ADR (ADXN) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Addex Therapeutics Ltd. Sponsored ADR is one of 1019 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks ...

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.The Dow traded down 0.16% to 41,175.13 while the NASDAQ fell 0.03% to 17,720.68. The S&P 500 also fell, dropping, 0.01% to 5,616.66.Check This Out: Jim Cramer Believes In Dell CEO, Doesn’t Like B&G FoodsLeading and Lagging SectorsInformation technology shares climbed by 0.5% on Tuesday.In trading on Tuesday, energy shares fell by 0.6%.Top HeadlineHain Celestial Group, Inc. HAIN reported better-tha ...

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Sympos ...